CA-OV-VSV / Cytonus Therap - LARVOL DELTA

Cytonus Therapeutics to Present Preclinical Data for Systemically Delivered Oncolytic Virus Program for Treating Metastatic Cancers at AACR 2022 (Businesswire) - "Cargocytes loaded with an Oncolytic Virus (CA-OV-VSV) are engineered to actively home, migrate, and penetrate into tumor micrometastatic foci, hours after intravenous administration. Dr. Klemke will share data demonstrating striking infiltration of engineered Cargocytes into solid tumors in in vivo models of metastatic Triple Negative Breast Cancer (TNBC), localizing and shielding the company’s proprietary Oncolytic Virus construct from immune neutralization and clearance....These results highlight the capabilities of Cytonus’ innovative Cargocyte™ platform in addressing solid tumor penetration challenges."

Preclinical • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer